BRAF基因检测在甲状腺癌诊疗中的研究进展

doi:10.3969/j.issn.1671-7171.2017.10.024

摘要
图/表
参考文献
相关文章 (15)

[1]阎玉芹.全球甲状腺结节及甲状腺癌的流行趋势及其原因分析[J].中华地方病志,2013,32(3):239-240.
[2]Jemal A,Siegel R,Ward E,et al.Cancer statistics,2008[J].CA Cancer J Clin,2008,58(2):71-96.
[3]Bonaconsa M,Colavito V,Pifferi F,et al.Cell clocks and neuronal networks:neuron ticking and synchronization in aging and aging-related neurodegenerative disease[J].Curr Alzheimer Res,2013,10(6):597-608.
[4]王萍,王颜刚,赵文娟,等.甲状腺乳头状癌BRAF基因突变及RET／PTC基因重排与血小板源性生长因子B表达的相关性研究[J].中华内科学杂志,2012,5(12):987-991.
[5]Lloyd RV,Baehler D,Khanafshar E.Papillary thyroid carcinoma variants [J].Head Neck Pathol,2011,5(1):51-56.
[6]李小强,张惠箴,蒋智铭,等.甲状腺乳头状癌中BRAF基因的表达及意义[J].临床与实验病理学杂志,2012,28(9):991-995.
[7]Guan H,Ji M,Bad R,el al.Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer[J].J Clin Endocrinol Metab,2009,94(5):1612-1617.
[8]Zhang Q,Song F,Zheng H,et al.Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population [J].Thyroid,2013,23(1):38-44.
[9]Marchetti I,lenvasi G,Mazzanti CM,et al.Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection:an easy tool to improve the preoperative diagnosis[J].Thyrvid,2012,22(3):292-298.
[10]Ohori NP,Nikiforova MN,Schoedel KE,et al.Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance"[J].Cancer Cytopathol,2010,118(1):17-23.
[11]Hassell LA,Gillies EM,Dunn ST.Cytologic and molecular diagnosis of thyroid cancers:is it time for routine reflex testing[J].Cancer Cytopathol,2012,120(1):7-17.
[12]Mallick UK,American Thyroid Association.The revised American Thyroid Association management guidelines 2009 for patients with differentiated thyroid cancer:an evidence-based risk-adapted approach[J].Clin Oncol(R Coll Radi01),2010,22(6):472-474.
[13]Li C,Lee KC,Schneider EB,et al.BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer:a meta-analysis[J].J Clin Endocrinol Metab,2012,97(12):4559-4570.
[14]Barollo S,Pennelli G,Viandlo F,et al.BRAF in primary and recurren papillary thyroid Cancers:the relationship with ¹³¹I and 2-[18F]fluoro-2-deoxy-D-glucose uptake ahility[J].Eur J Endoerinol,2010,163(4):659-663.
[15]Kleos RT,Ringel MD,Knopp MV,et al.Phase II trial of sorafenib in metastatic thyroid cancer[J].J Clin Oncol,2009,27(10):1675-1684.